FIG. 1.

Anti-CD3 and rapamycin monotherapy in diabetic NOD mice. Female diabetic NOD mice were grouped based on glycemia levels (300–349 [gray bar] and 350–400 mg/dl [white bar]) and treated with various anti-CD3 dosages. Percentages of diabetes reversal and number of mice in each group are shown (A). Glucose levels of the eight NOD mice with 300–349 mg/dl glycemia and treated with three 50-μg doses of anti-CD3 (75% diabetes reversal) are shown (B). Female diabetic NOD mice with 300–400 mg/dl glycemia were treated with rapamycin alone (1 mg/kg daily during the entire time of observation [□]) or anti-CD3 alone (50 μg × 3 doses at days 0, 1, and 2 [♦]). Percentage of diabetes reversal and number of mice are shown (C).